Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese
 female patients with overactive bladder (OAB). Patients received either placebo and trospium
 chloride XR or placebo only. The study assessed the change from baseline in urinary
 frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The
 study was 14 weeks in duration.
Inclusion Criteria:

 -  OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence

 -  Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine
 patches, etc., for 6 months prior to the screening visit).

 -  Obese

 Exclusion Criteria:

 -  Chronic kidney failure

 -  Abdominal bypass surgery for obesity

 -  Moderate or severe memory impairment

 -  Uncontrolled narrow angle glaucoma

 -  Uncontrolled systemic disease

 -  Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine),
 Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia